ArticleJournal of medical virology2025
Seroepidemiology of Human Non-Species A Rotavirus Infections in Valencia, Spain.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Whole-genome characterization and pathogenicity of novel human-porcine reassortant rotavirus strains G9P[7] and G1P[7] in China.Veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Species A rotavirus (RVA) is a major cause of acute gastroenteritis in children. However, three other rotavirus species (RVB, RVC, and RVH) are also able to infect humans. It has been suggested that vaccination against RVA could facilitate an increase of non-A rotavirus infections. We investigated the antibody prevalence against RVA, RVB, RVC, and RVH in 420 human sera collected between 2020 and 2022 from different age groups in Valencia (Spain). Antibody prevalence rates to RVA, RVB, RVC, and RVH were 79.3%, 17.9%, 18.8%, and 14.5%, respectively. Antibody titers against RVA remained consistent across the different age groups, and RVB showed low titers except in younger individuals. RVC-specific antibodies peaked in children 5-10 years of age, whereas RVH exhibited the highest titers in the elderly. The detection of antibodies against non-A rotaviruses in humans in Spain, for the first time against RVB and RVH, highlights the need for their surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.